← back to search

David S. Lawrence

University of London · GB
Area of research
Epidemiology · Infectious Diseases
Research interest
Research interests include Fungal Infections and Studies, Antifungal resistance and susceptibility, Nail Diseases and Treatments, and HIV/AIDS Research and Interventions.
h-index
32
citations
4,321
works
167
NIH funding
primary concept
Medicine
email

Recent publications

Causes of hospitalisation among people living with HIV worldwide, 2014–23: a systematic review and meta-analysis
The Lancet HIV 2025cited by 11position: middledoi
Recent Antiretroviral Therapy Initiation Is Associated With Increased Mortality Risk in Human Immunodeficiency Virus–associated Cryptococcal Meningitis: An Analysis of Clinical Trial Data From Africa
Clinical Infectious Diseases 2025cited by 6position: middledoi
Reducing HIV incidence and mortality: two sides of the same coin in the approach to ending AIDS
The Lancet HIV 2025cited by 4position: middledoi
Personalised risk-prediction tools for cryptococcal meningitis mortality to guide treatment stratification in sub-Saharan Africa: a prognostic modelling study based on pooled analysis of two randomised controlled trials
The Lancet Global Health 2025cited by 4position: middledoi
Ethical issues surrounding the implementation of long-acting injectable antiretroviral therapy in sub-Saharan Africa
International Health 2025cited by 3position: middledoi
Diagnostic accuracy of the <scp>WHO</scp> clinical staging system for detection of immunologically defined advanced <scp>HIV</scp> disease: A systematic review and meta‐analysis
HIV Medicine 2025cited by 2position: middledoi
Interventions to Support People With HIV Following Hospital Discharge: A Systematic Review
Open Forum Infectious Diseases 2025cited by 2position: middledoi
Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA)
Wellcome Open Research 2025cited by 2position: middledoi
Epstein–Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trial
The Lancet HIV 2025cited by 2position: middledoi
Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM
The Lancet Infectious Diseases 2024cited by 247position: middledoi
Development and validation of quantitative PCR assays for HIV-associated cryptococcal meningitis in sub-Saharan Africa: a diagnostic accuracy study
The Lancet Microbe 2024cited by 15position: middledoi
Tracking Cryptococcal Meningitis to Monitor HIV Program Success During the Treat All Era: An Analysis of National Data in Botswana
Clinical Infectious Diseases 2024cited by 9position: middledoi
Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort Study
Clinical Infectious Diseases 2024cited by 7position: middledoi
Two-drug regimens for the treatment of HIV in Africa
The Lancet HIV 2024cited by 5position: middledoi
Cryptococcal meningitis
Nature Reviews Disease Primers 2023cited by 115position: middledoi
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation study
The Lancet HIV 2023cited by 17position: middledoi
Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis
Journal of Antimicrobial Chemotherapy 2023cited by 12position: middledoi
Pathways to care with HIV-associated cryptococcal meningitis in Botswana and Uganda: Findings from a qualitative methods study
SSM - Qualitative Research in Health 2023cited by 5position: firstdoi
Clinical research for life-threatening illnesses requiring emergency hospitalisation: a critical interpretive synthesis of qualitative data related to the experience of participants and their caregivers
Trials 2023cited by 3position: firstdoi
Translating evidence into global impact: lessons for HIV research and policy development from the AMBITION trial
The Lancet Global Health 2023cited by 2position: middledoi
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
LSTM Online Archive (Liverpool School of Tropical Medicine) 2022cited by 219position: middle
Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial
The Lancet Global Health 2022cited by 29position: firstdoi
Laboratory Evaluation of the VISITECT Advanced Disease Semiquantitative Point-of-Care CD4 Test
JAIDS Journal of Acquired Immune Deficiency Syndromes 2022cited by 18position: middledoi
Decision making in a clinical trial for a life-threatening illness: Therapeutic expectation, not misconception
Social Science & Medicine 2022cited by 15position: firstdoi
Association of Hyponatremia on Mortality in Cryptococcal Meningitis: A Prospective Cohort
Open Forum Infectious Diseases 2022cited by 12position: middledoi
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?
Clinical Infectious Diseases 2022cited by 12position: middledoi
The acceptability of the AMBITION-cm treatment regimen for HIV-associated cryptococcal meningitis: Findings from a qualitative methods study of participants and researchers in Botswana and Uganda
PLoS neglected tropical diseases 2022cited by 11position: firstdoi
Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis
Journal of Antimicrobial Chemotherapy 2022cited by 7position: middledoi
Single-Dose Amphotericin B for Cryptococcal Meningitis
New England Journal of Medicine 2022cited by 5position: firstdoi
Reversal of CSF HIV-1 Escape during Treatment of HIV-Associated Cryptococcal Meningitis in Botswana
Biomedicines 2022cited by 5position: middledoi

Grants

Collaborative Research: Permafrost Carbon Network: Synthesizing flux observations for benchmarking model projections of permafrost carbon exchange
NSF1931332$434,5632019–2024PIRePORTER
Collaborative Research: The Climatic Role of Permafrost-As permafrost thaws, could a weakening terrestrial freezer and an increasingly leaky bathplug amplify Arctic climate change?
NSF1304220$160,1192013–2018PIRePORTER
Collaborative Research: Type 1 - Improved Cold Region Hydrology Process Representation as a Cornerstone of Arctic Biogeochemical Modeling (L02170157)
NSF1048997$458,1672011–2015PIRePORTER

Frequent collaborators

Joseph N Jarvis · University of London31 papers (2018–2025)Thomas S. Harrison · The Heart Research Institute16 papers (2018–2025)David B. Meya · University of Minnesota11 papers (2020–2025)Tshepo Leeme · London School of Hygiene & Tropical Medicine9 papers (2018–2024)Henry C. Mwandumba · University of Liverpool8 papers (2020–2025)Janet Seeley · London School of Hygiene & Tropical Medicine7 papers (2021–2025)David R. Boulware · University of Minnesota7 papers (2020–2025)Chiratidzo E. Ndhlovu · University of Cape Town6 papers (2020–2025)Graeme Meintjes · Johns Hopkins Medicine6 papers (2020–2025)Mosepele Mosepele · University College London6 papers (2018–2025)Mark W. Tenforde · Centers for Disease Control and Prevention6 papers (2018–2024)Olivier Lortholary · Institut Pasteur5 papers (2019–2025)Agnes Ssali · London School of Hygiene & Tropical Medicine5 papers (2021–2023)Jayne Ellis · University of Liverpool4 papers (2023–2025)Lillian Tugume · Infectious Diseases Institute4 papers (2020–2025)Síle F. Molloy · London School of Hygiene & Tropical Medicine4 papers (2018–2025)Conrad Muzoora · Mbarara University of Science and Technology4 papers (2020–2025)Nathan Ford · London School of Hygiene & Tropical Medicine4 papers (2023–2025) · 4 papers (2025–2025)Timothée Boyer‐Chammard · Institut Pasteur4 papers (2018–2025)